What is HC Wainwright's Estimate for VIR FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Vir Biotechnology to a loss of $0.89 per share from a projected loss of $1.89.
• The firm maintained its Buy rating and $22 price target. Its FY2027 estimate is a loss of $1.99 per share.
• Vir reported a quarterly loss of $0.57 per share, better than the $0.75 loss analysts expected. Separately, its tobevibart-elebsiran combination met primary and secondary endpoints in the Phase 3 ECLIPSE 1 trial.

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities researchers at HC Wainwright lifted their FY2026 earnings estimates for Vir Biotechnology in a research note issued to investors on Monday, November 9th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.89) per share for the year, up from their previous forecast of ($1.89). HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Vir Biotechnology's current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Vir Biotechnology's Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.46) EPS and FY2027 earnings at ($1.99) EPS.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.18. The company had revenue of ($0.19) million during the quarter, compared to the consensus estimate of $0.98 million. During the same quarter last year, the firm earned ($1.17) EPS. The business's revenue for the quarter was down 178.3% on a year-over-year basis.

VIR has been the topic of several other research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vir Biotechnology in a research note on Friday, October 2nd. Zacks Research upgraded Vir Biotechnology from a "strong sell" rating to a "hold" rating in a research report on Wednesday, November 4th. Morgan Stanley lifted their price objective on Vir Biotechnology from $25.00 to $28.00 and gave the stock an "overweight" rating in a research report on Tuesday. Raymond James Financial reissued a "strong-buy" rating on shares of Vir Biotechnology in a report on Monday, September 28th. Finally, Wall Street Zen upgraded shares of Vir Biotechnology from a "hold" rating to a "buy" rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $22.57.

Vir Biotechnology Stock Performance

Shares of VIR opened at $13.15 on Wednesday. The business's fifty day moving average price is $11.13 and its two-hundred day moving average price is $9.68. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -10.44 and a beta of 1.70. Vir Biotechnology has a 52 week low of $5.32 and a 52 week high of $14.38.

Insider Activity

In other news, EVP Vanina de Verneuil sold 2,407 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total value of $26,717.70. Following the transaction, the executive vice president directly owned 110,193 shares in the company, valued at $1,223,142.30. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Vir Biotechnology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC bought a new stake in shares of Vir Biotechnology in the 2nd quarter valued at about $25,034,000. Parkman Healthcare Partners LLC bought a new position in Vir Biotechnology during the 2nd quarter worth approximately $4,843,000. ARCH Venture Management LLC bought a new position in Vir Biotechnology during the 2nd quarter worth approximately $129,353,521. BlackRock Inc. bought a new position in Vir Biotechnology during the 2nd quarter worth approximately $210,712,000. Finally, Bank of America Corp DE acquired a new position in Vir Biotechnology during the second quarter valued at approximately $11,642,000. Institutional investors own 65.32% of the company's stock.

Key Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Vir said its combination of tobevibart and elebsiran met the primary and secondary endpoints in the pivotal Phase 3 ECLIPSE 1 trial for chronic hepatitis D. The result strengthens the case for the regimen as a potential treatment and helped drive the recent surge in the shares. Article: Vir hepatitis D drug succeeds in first pivotal study
• Positive Sentiment: Morgan Stanley raised its price target to $28 and reaffirmed an “overweight” rating; HC Wainwright also reiterated its “buy” rating with a $22 target. These upgrades reflect optimism following the trial result.
• Neutral Sentiment: The Phase 3 success is an important milestone, but the recent rally may leave the stock vulnerable to profit-taking as investors assess the treatment’s regulatory prospects, market opportunity and competition. A recent analysis also questioned whether the shares are already fairly valued after the news. Article: Vir Biotechnology: Fairly Valued After Phase 3 Success?

About Vir Biotechnology

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments. The company's pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.